All In Biotech

Drug Trial Radar · NCT07001748

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Protocol EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

148

Planned (sponsor's estimate)

Start

Oct 24, 2025

Primary completion

May 30, 2030

Study completion May 30, 2031

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jun 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will administering paclitaxel chemotherapy directly into your abdominal cavity, in addition to chemotherapy given through a vein in your arm help you live longer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your gastric cancer. The usual approach is defined as care most people get for gastric cancer. If you decide to take part in this study, you will first receive a surgical procedure called a diagnostic laparoscopy. This will help the study doctors learn more about your gastric cancer. Laparoscopy is a minimally invasive surgery for which you will be placed under general anesthesia. Then the surgeon will make small incisions (5mm) on your belly through which a camera and thin instruments are introduced to evaluate the abdomen. This procedure takes about 1 hour to complete. Your study group will be assigned during the surgery. The study groups are described further in the 'What are the study groups?' section below. If you are placed into the study group 1, you will not have an intraperitoneal port (a small device which is placed under the skin and fat of your upper abdomen and a tube that is placed into the abdomen). If you are placed into the study group 2, you will have an intraperitoneal port placed. The reason is that in addition to standard chemotherapy, which is given through a vein in your arm, this port will be used to deliver the medication paclitaxel directly inside your abdomen when you are ready to start study treatment. It is important to know that you will not know your study group until after the surgery is over. This is because information that is learned during the surgery will help determine which study group you are put in. Once you have fully healed from this surgery, you will start study treatment. Depending on which study group you are assigned, you will either receive a standard chemotherapy regimen (the regimen will be chosen by you and your doctor) if you are in study group 1, or paclitaxel through a tube in your belly plus chemotherapy given through a vein in your arm if you are in study group 2. All participants will get treatment for three (3) months after which you will undergo reevaluation. If the disease is under control or responding to treatment, you may continue the assigned treatment until your disease gets worse, the side effects become too severe, or you may be offered a surgical procedure to remove the cancer if the amount of disease is low and can be completely removed as determined by a surgeon. There is a very small chance that during the laparoscopy surgical procedure, the doctor might find something called "intra-abdominal adhesions". These are areas where the stomach has healed previously and created scar tissue. If this scar tissue prevents the surgeon from being able to place a port in the correct area, you would be ineligible to receive the study treatment. If this happens, you may still receive standard of care therapy after your surgery, but you will not be able to continue on the study. If you have more questions about this, you can ask your surgeon or the study team to help. After you finish your study treatment, your doctor or study team will watch you for side effects. They will continue to follow your condition every three (3) months during the first two (2) years, then every six (6) months until year 5. You may be reevaluated with Chest/Abdomen/Pelvis scans every three-six (3-6) months for up to five (5) years if decided by your doctor.

Conditions

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Peritoneal Carcinomatosis

Interventions

  • Standard of Care ChemotherapyDrug

    The most common regimens are FOLFOX, CAPOX, FLOT, CF, and CX. Other local institutional standard of care regimens as well as targeted agents for gastric/GEJ adenocarcinoma are allowed.

  • Biospecimen CollectionProcedure

    Plasma is to be submitted at baseline and every three months for the first year or until progression, whichever comes first. For patients who have progression, their last plasma sample should be at time of progression.

  • Computed TomographyProcedure

    Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.

  • Diagnostic LaparoscopyProcedure

    After induction of general anesthesia, administration of preoperative antibiotics and placement of appropriate laparoscopic ports, peritoneal lavage will be performed by instillation of 200 ml of normal saline in the left upper quadrant and allowed to dwell for 5 minutes after which it will be aspirated for cytology. Extent of peritoneal disease burden will be ascertained as per the Peritoneal Cancer Index (PCI) scoring system as outlined in Appendix V.

  • Intraperitoneal Port PlacementProcedure

    Patients assigned to Arm B will undergo placement of indwelling tunneled intraperitoneal port with Teflon cuff following Step 1 randomization and during the diagnostic laparoscopy procedure.

  • Magnetic Resonance ImagingProcedure

    Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.

  • Intraperitoneal PaclitaxelDrug

    Patients on Arm B will start systemic therapy + intraperitoneal paclitaxel as early as the day after Step 1 randomization and must start within 30 calendar days (including holidays) after Step 1 randomization as per the schedule shown in the table below. Therapy will be administered on Days 1 and 8 of a 21-day cycle for 4 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (Phase II)Time frame: From randomization to progression or death without documentation of progression, assessed up to 5 years.
  2. Overall survival (Phase III)Time frame: From randomization to the date of death, of any cause, assessed up to 5 years

Locations

78 sites in 1 country. Site status is shown where the registry gives one.

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Recruiting

  • UCHealth University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • Smilow Cancer Hospital-Derby Care Center

    Derby, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center-Fairfield

    Fairfield, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center at Greenwich

    Greenwich, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center - Guilford

    Guilford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Yale-New Haven Hospital North Haven Medical Center

    North Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center at Long Ridge

    Stamford, Connecticut · Recruiting

  • Smilow Cancer Hospital-Torrington Care Center

    Torrington, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut · Recruiting

  • Smilow Cancer Hospital-Waterbury Care Center

    Waterbury, Connecticut · Recruiting

  • Smilow Cancer Hospital Care Center - Waterford

    Waterford, Connecticut · Recruiting

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Old Irving Park

    Chicago, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois · Recruiting

  • Northwestern Medicine Oak Brook

    Oak Brook, Illinois · Recruiting

  • Memorial Hospital East

    Shiloh, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois · Recruiting

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • University Medical Center New Orleans

    New Orleans, Louisiana · Recruiting

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital

    Grand Rapids, Michigan · Recruiting

  • West Michigan Cancer Center

    Kalamazoo, Michigan · Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri · Recruiting

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Siteman Cancer Center-South County

    St Louis, Missouri · Recruiting

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.